5770-42-3

Basic information

• Product Name: 6-METHYLAMINO-1,3-DIMETHYLURACIL
• Synonyms: 1,3-dimethyl-6-(methylamino)pyrimidine-2,4-dione;1,3-dimethyl-6-(methylamino)pyrimidine-2,4-quinone;1,3-Dimethyl-6-methylamino-1H-pyrimidine-2,4-dione
• CAS NO: 5770-42-3
• Molecular Formula: C₇H₁₁N₃O₂
• Molecular Weight: 169.18
• Mol File: 5770-42-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 259.8°Cat760mmHg
• Flash Point: 110.9°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 0.0127mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: 6-METHYLAMINO-1,3-DIMETHYLURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYLAMINO-1,3-DIMETHYLURACIL(5770-42-3)
• EPA Substance Registry System: 6-METHYLAMINO-1,3-DIMETHYLURACIL(5770-42-3)

Safety Data

• Hazardous Substances Data: 5770-42-3(Hazardous Substances Data)

Usage

General Description

6-Methylamino-1,3-dimethyluracil is a chemical compound also known as the drug Theocap. It is a xanthine alkaloid derivative that acts as a central nervous system stimulant and bronchodilator. It is commonly used to treat asthma and other respiratory conditions due to its ability to relax the smooth muscles of the airways. The compound also has a stimulating effect on the heart and increases the force of contractions, making it useful in the treatment of certain heart conditions. 6-Methylamino-1,3-dimethyluracil works by inhibiting the enzyme phosphodiesterase, leading to increased levels of cyclic adenosine monophosphate (cAMP) and activation of protein kinase A, which ultimately results in smooth muscle relaxation and increased bronchodilation.

InChI:InChI=1/C7H11N3O2/c1-8-5-4-6(11)10(3)7(12)9(5)2/h4,8H,1-3H3

Upstream product

• 6972-27-6 1,3-Dimethyl-6-chlorouracil 
• 74-89-5 methylamine 
• 98333-72-3 1,3-dimethyl-5-bromo-6-methylaminopyrimidine-2,4-dione 
• 13332-78-0 di-(1,3-dimethyl-6-methylaminouracil-5-yl)methane 
• 1149-23-1 diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 17260-79-6 1-benzyl-3-carbamoyl-1,4-dihydroquinoline 
• 52126-36-0 diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate-4,4-d₂ 
• 4229-44-1 N-methylhydroxyamine hydrochloride 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 
• 510773-30-5 6-(hydroxy-methyl-amino)-1,3-dimethyl-1H-pyrimidine-2,4-dione 
• 769-42-6 1,3-dimethylbarbituric acid 
• 6642-31-5 6-Amino-1,3-dimethylbarbituric acid 
• 49846-86-8 6-cyano-1,3-dimethyluracil 

Downstream Products

• 1467-79-4 NCNMe₂ 
• 2278-16-2 3,4,6-trimethyl-5,7-dioxo-4,5,6,7-tetrahydro-1,2,3-triazolo<4,5-d>pyrimidine 
• 13332-78-0 di-(1,3-dimethyl-6-methylaminouracil-5-yl)methane 
• 105159-32-8 4-methyl-N-(2-phenyl-2-(phenylamino)ethyl)benzenesulfonamide 
• 105159-26-0 N-{2-[4-(1,3-Dimethyl-6-methylamino-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylmethyl)-phenylamino]-2-phenyl-ethyl}-4-methyl-benzenesulfonamide 
• 105159-22-6 1,3-Dimethyl-6-methylamino-5-{4-[5-phenyl-3-(toluene-4-sulfonyl)-imidazolidin-1-yl]-benzyl}-1H-pyrimidine-2,4-dione 
• 105159-20-4 C₄₃H₄₄N₄O₄S₂ 
• 97511-53-0 1,3,5-trimethyl-6-methylamino-1H-pyrimidine-2,4-dione 
• 113518-45-9 6-(p-tosylamidomethyl)phenanthridine 
• 115285-38-6 N-[2-(1,3-Dimethyl-6-methylamino-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylmethyl)-phenanthridin-6-ylmethyl]-4-methyl-benzenesulfonamide 
• 115173-61-0 N-[2-(1,3-Dimethyl-6-methylamino-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylmethyl)-5,6-dihydro-phenanthridin-6-ylmethyl]-4-methyl-benzenesulfonamide 
• 115173-60-9 1,3-Dimethyl-6-methylamino-5-[2-(toluene-4-sulfonyl)-1,2,3,12b-tetrahydro-imidazo[1,5-f]phenanthridin-7-ylmethyl]-1H-pyrimidine-2,4-dione 
• 105159-30-6 C₈H₁₂⁽²⁾HN₃O₂ 
• 2672-58-4 1,3,5-tris-(methoxycarbonyl)benzene 

Relevant articles and documents

A natural product four methyl uric acid fully synthetic method

The invention relates to a total synthesis method for a natural product tetramethyl uric acid. The method comprises the following steps: (1) using 1,3-dimethyl barbituric acid as a raw material for synthesis to obtain an intermediate 6-substitued-1,3-dimethyl pyrimidine-2,4-diketone; (2) synthesizing an intermediate 1,3-dimethyl-6-methylamino pyrimidine-2,4-diketone; (3) synthesizing an intermediate 1,3-dimethyl-5-substitued-6-methylamino pyrimidine-2,4-diketone; (4) synthesizing an intermediate 1,3-dimethyl-5,6-dimethylamino pyrimidine-2,4-diketone; (5) synthesizing a target compound 1,3,7,9-tetramethyl uric acid. The method is convenient for synthesis, has a higher yield, and can ease the demand on tetramethyl products to a certain degree.

Two-step synthetic approach to 6-substituted pyrido[2,3-d]pyrimidine(1H,3H) -2,4-diones from 6-amino-, 6-alkylamino-, and 6-arylamino-1,3-dimethyluracils

The Mannich reaction of 7-aryl-5,6-dihydropyrido[2,3-d]pyrimidines 3, easily accessible by condensation of 6-amino-1,3-dimethyluracil (1) with Mannich bases 2a-c, gives rise to a mixture of 7-aryl-6-(N,N-dimethylaminomethyl) pyrido[2,3-d]pyrimidines 6 and

Structural characterization of closely related mononuclear CuII complexes of 5-nitrosooxime pyrimidines. A combined X-ray and EPR study

In reactions of trans-bis(oximato)complexes [1L2Cu(H2O)2] and [2L2Cu(H2O)2] (H1L=6-amino-1,3-dimethyl-5-nitrosouracil and H2L=6-methylamino-1,3-dimethyl-5-nitrosouracil) with [Cu(bipy)2]2+, one of the pyrimidine ligands was replaced by bipy (bipy=2,2′-bipyridine) affording mononuclear mixed-ligand complexes of the type [LCu(bipy)X] (X is H2O, EtOH or Cl-). Under the reaction conditions, the 6-methylamino group of H2L undergoes hydrolysis leading to violuric acid (5-nitroso-2,4,6-trioxopyrimidine; H3L). Three closely related mononuclear copper(II) complexes, [Cu(1L)(bipy)(H2O)]ClO4 · H2O (1), [Cu(3L)(bipy)(EtOH)][Cu(3L)(ClO 4)(bipy)(EtOH)]ClO4 (2) and [Cu(3L)Cl(bipy)] · 0.5H2O (3), have been prepared, their crystal structures were determined and an EPR study was carried out. Acta Chemica Scandinavica 1997.